AU2021348219A1 - Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof - Google Patents

Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof Download PDF

Info

Publication number
AU2021348219A1
AU2021348219A1 AU2021348219A AU2021348219A AU2021348219A1 AU 2021348219 A1 AU2021348219 A1 AU 2021348219A1 AU 2021348219 A AU2021348219 A AU 2021348219A AU 2021348219 A AU2021348219 A AU 2021348219A AU 2021348219 A1 AU2021348219 A1 AU 2021348219A1
Authority
AU
Australia
Prior art keywords
conjugate
mice
radionuclide
chelator
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021348219A
Other languages
English (en)
Inventor
Amal SAIDI
Tania STALLONS
Julien Torgue
Amy Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orano Med Theranostics
Original Assignee
Orano Med Theranostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orano Med Theranostics filed Critical Orano Med Theranostics
Publication of AU2021348219A1 publication Critical patent/AU2021348219A1/en
Assigned to ORANO MED THERANOSTICS reassignment ORANO MED THERANOSTICS Request for Assignment Assignors: ORANO MED MANUFACTURING
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021348219A 2020-09-28 2021-09-22 Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof Pending AU2021348219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306109.8 2020-09-28
EP20306109.8A EP3973999A1 (en) 2020-09-28 2020-09-28 Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
PCT/EP2021/076107 WO2022063850A1 (en) 2020-09-28 2021-09-22 Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof

Publications (1)

Publication Number Publication Date
AU2021348219A1 true AU2021348219A1 (en) 2023-03-09

Family

ID=74180915

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021348219A Pending AU2021348219A1 (en) 2020-09-28 2021-09-22 Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof

Country Status (21)

Country Link
US (1) US20230372552A1 (cg-RX-API-DMAC7.html)
EP (2) EP3973999A1 (cg-RX-API-DMAC7.html)
JP (1) JP7824281B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230078690A (cg-RX-API-DMAC7.html)
CN (1) CN116322798A (cg-RX-API-DMAC7.html)
AU (1) AU2021348219A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003690A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189680A1 (cg-RX-API-DMAC7.html)
DK (1) DK4188457T3 (cg-RX-API-DMAC7.html)
ES (1) ES2989009T3 (cg-RX-API-DMAC7.html)
FI (1) FI4188457T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241285T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068360T2 (cg-RX-API-DMAC7.html)
IL (1) IL300486A (cg-RX-API-DMAC7.html)
LT (1) LT4188457T (cg-RX-API-DMAC7.html)
PL (1) PL4188457T3 (cg-RX-API-DMAC7.html)
PT (1) PT4188457T (cg-RX-API-DMAC7.html)
RS (1) RS65994B1 (cg-RX-API-DMAC7.html)
SI (1) SI4188457T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400392T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022063850A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2026150109A1 (en) 2025-01-10 2026-07-16 Molecular Partners Ag Mesothelin-specific binding constructs and their use in radiotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
US20150217006A1 (en) * 2014-02-06 2015-08-06 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
CA3050094C (en) 2017-01-12 2024-01-02 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes

Also Published As

Publication number Publication date
EP4188457B1 (en) 2024-07-03
CN116322798A (zh) 2023-06-23
EP3973999A1 (en) 2022-03-30
EP4188457A1 (en) 2023-06-07
ES2989009T3 (es) 2024-11-25
JP7824281B2 (ja) 2026-03-04
PL4188457T3 (pl) 2025-01-07
WO2022063850A1 (en) 2022-03-31
LT4188457T (lt) 2024-12-27
SI4188457T1 (sl) 2025-01-31
SMT202400392T1 (it) 2024-11-15
HUE068360T2 (hu) 2024-12-28
JP2023542218A (ja) 2023-10-05
RS65994B1 (sr) 2024-10-31
BR112023003690A2 (pt) 2023-04-04
CA3189680A1 (en) 2022-03-31
DK4188457T3 (da) 2024-08-26
IL300486A (en) 2023-04-01
HRP20241285T1 (hr) 2025-01-03
US20230372552A1 (en) 2023-11-23
KR20230078690A (ko) 2023-06-02
FI4188457T3 (fi) 2024-09-23
PT4188457T (pt) 2024-09-10

Similar Documents

Publication Publication Date Title
JP7358430B2 (ja) Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
US5804157A (en) Peptide compositions and method of radiolabeling
AU2550095A (en) Somatostatin binding peptide-metal chelate conjugates
EP4188457B1 (en) Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
KR20140053819A (ko) 방사선요법용 177루테튬-표지 봄베신 유사체
JP7773679B1 (ja) Sstr2を標的とする化合物、並びにその調製方法、および使用
US20240100202A1 (en) Psma-targeting conjugate and uses thereof
RU2821944C2 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANTS TO ORANO MED MANUFACTURING

PC1 Assignment before grant (sect. 113)

Owner name: ORANO MED THERANOSTICS

Free format text: FORMER APPLICANT(S): ORANO MED MANUFACTURING